MAKE SURE YOUR DENTIST IS AN ADA MEMBER!: ADA Members Adhere to Strict Code of Ethics and Conduct. You should make sure you are SEEING AN ADA MEMBER DENTIST! Visit ADA Find-A-Dentist to Find One Near YOU

Ninth District Headquarters Office - Hawthorne, NY

2025 Ninth District President

Dr. Renuka Bijoor

ADA Update: a new login experience

We’re updating how you log in to your NYSDA and ADA account.

Learn more

RENEW YOUR MEMBERSHIP TODAY!

3 EASY WAYS TO PAY 1 ONLINE: nysdental.org/renew 2 MAIL: Return dues stub and payment 3 PHONE: 1-800-255-2100

RENEW TODAY!

Member Assistance Program (MAP)

Life comes with challenges, but your new Member Assistance Program (MAP) is here to help. This free, confidential benefit is available to you and your household, offering resources and services to support mental health, reduce stress, and make life easier.

LEARN MORE

Welcome to the Ninth District Dental Association

The Ninth District Dental Society was formed in 1909 and renamed to the Ninth District Dental Association in 2002. We have a membership of over 1500 dentists in 5 counties: Westchester, Rockland, Dutchess, Orange and Putnam.

In its quest to serve both the public and the profession, the Ninth District embodies the highest ideals.

The mission of the 9^th District Dental Association is to serve and support its members and the public by improving the oral health of our community through Advocacy, Continuing Education and Camaraderie.

The Ninth District Dental Association, in Partnership with the New York State Dental Foundation (NYSDF), will be hosting an

Oral Health Screening Event
with the Hudson Valley Renegades and
Sponsored by Henry Schein Cares Foundation

September 5, 2025
6:00 pm - 9:00 pm

*** * * * * * * * * ***

Don't Miss the 9th District Dental Association's General Meeting
Wednesday, September 17, 2025

The Westchester Manor
140 Saw Mill River Road
Hastings-on-Hudson, NY

Register

Mahnaz Fatahzadeh, D.M.D., M.S.D.
Completed her Oral Medicine fellowship and MSD degree at the Rutgers School of Dental Medicine where she holds a faculty appointment as a professor of Oral Medicine and as an attending at the University hospital. Dr. Fatahzadeh is a diplomat of American Board of Oral Medicine and director of pre and post-doctoral oral medicine training and Oral Mucosal Diseases Clinic at the Rutgers School of Dental Medicine.

"Orofacial Manifestations of Systemic Diseases"

Course Objectives

Oral cavity is readily accessible for inspection and a gateway for assessment of general health. In fact, many systemic conditions affecting organs far from the head and neck region could manifest in the orofacial region, sometimes prior to their diagnosis. Abnormalities detected in the orofacial region may also represent complications related to medical therapy or raise concerns about substance abuse. This program provides illustrative examples of orofacial findings associated with diagnosed or subjectively silent systemic disease, medical therapy and substance abuse. Relevant signs, symptoms, and diagnostics are reviewed and the potential role of oral health care providers in recognition, referral, follow-up and overall management is emphasized.

Meeting Exhibitors (so far): (company names are links to their websites)

After Hours Cleaning

Altfest Personal Wealth Management

BonaDent Dental Labs

DDSMatch

Epstein Practice Brokerage

Garfield Refining Company

General Refining

Komet

M&T Bank

MLMIC Insurance Company

Orion Dental Solutions

Singular Anesthesia Services

Latest News Around the Tripartite

FDA Issues Health Care Stakeholders Update

Apr 5, 2024

The United States Food and Drug Administration (FDA) has issued its weekly regulatory update for stakeholders. You can read the FDA regulatory update for stakeholders below.

April 5, 2024
Dear Colleague,
While the FDA continues to focus on protecting the public’s health, using science to guide our decisions, and facilitating access to critical medical products, we also recognize the work of our public health partners. As public health advocates, we know that your work to better our country is invaluable. Your partnership, knowledge and engagement in the public health space are appreciated.
2024 Happy Spring

Updates

Spotlight!

It’s National Minority Health Month and this year’s theme is “Be the Source for Better Health.” We invite everyone to be the source for clinical trial information.
Share our clinical trial resources, available in Spanish and other languages: https://www.fda.gov/.../minority.../clinical-trial-diversity

Consumer Updates

Colorectal Cancer: What You Should Know About Screening
Colorectal Screening CU image

The evidence is clear - screening for colorectal cancer may save your life. Today, more and more people are choosing colorectal cancer screening. As a result, there is a steady decline in the number of older people getting and dying from colorectal cancer. Lower rates of smoking among Americans have also contributed to the decline in the past several years.

Read More

Is Food Safe if it Has Chemicals?
Is food safe graphic

You may have seen news or online content about chemicals in our foods. Perhaps you’re wondering, is a food safe to eat if it contains chemicals? All our food — like everything in the world — is made up of chemicals. The presence of a chemical alone isn’t what determines whether a food is safe to eat.

Read More

Know Which Medication Is Right for Your Seasonal Allergies
close-up of a dandelion; woman sneezing; man rubbing his eyes

Seasonal allergic rhinitis, the medical term for seasonal allergies and hay fever, can also trigger or worsen asthma and lead to other health problems, such as sinus infections (sinusitis) and ear infections. The U.S. Food and Drug Administration regulates several medications that offer allergy relief.

Read More

Guidance Documents

Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
The purpose of this guidance is to provide recommendations to applicants and testing site management on achieving and maintaining data integrity for the clinical and bioanalytical portions of bioavailability (BA) and bioequivalence (BE) studies submitted in support of investigational new drug applications (INDs), new drug applications (NDAs), and abbreviated new drug applications (ANDAs), and the bioanalytical portion of clinical pharmacologic studies supporting CDER-regulated biologic license applications (BLAs) as well as amendments and supplements to these applications.

Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements
This guidance expands upon and replaces the recommendations related to Master Files in the 2016 revised draft guidance (Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues). This approach of separating the 2016 revised draft guidance into discrete sections for ease of use is responsive to comments received from stakeholders.

Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues
This draft guidance expands upon and replaces the recommendations related to Master Files for new dietary ingredient notifications (NDINs) in the 2016 revised draft guidance. For more information, see Constituent Update: FDA Issues Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements.

Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry
This guidance provides instructions for the electronic submission of expedited individual case safety reports (ICSRs) from investigational new drug (IND)-exempt bioavailability (BA)/bioequivalence (BE) studies conducted to support abbreviated new drug applications (ANDAs) to FDA Adverse Event Reporting System (FAERS).

Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry
FDA is announcing the availability of a final guidance for industry entitled “Providing Regulatory Submissions in Electronic Format: IND Safety Reports.” This guidance finalizes the draft guidance of the same name published on October 30, 2019 (84 FR 58158), and describes the electronic format sponsors will be required to use when they electronically submit IND safety reports to CDER and CBER for serious and unexpected suspected adverse reactions, as required under 21 CFR 312.32(c)(1)(i).

View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.

Webinars and Virtual Workshops

Webinar - Draft Guidance: Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act
April 30, 2024; 1 - 2 p.m. ET
This draft guidance proposes updated recommendations to industry on cybersecurity considerations for cyber devices and for documentation in device premarket submissions. The Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions, in its current form, remains the Agency's current thinking on this topic until this draft guidance is finalized, at which time the finalized version of Section II.
Registration is not required.

FDA/CRCG Workshop: Considerations and Potential Regulatory Applications for a Model Master File
May 2 - 3, 2024
Day 1: Thu, May 2, 2024; 8:30 a.m. - 5:30 p.m. ET
Day 2: Fri, May 3, 2024; 8:30 a.m. - 3:50 p.m. ET
The purpose of this workshop is to engage stakeholders among model developers, industry, and FDA in a discussion on the concept, scope, and regulatory application of a Model Master File (MMF).

Register Here

View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts

About Us

The Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations. For more information, please contact us at: FDAStakeholderEngagement@fda.hhs.gov.